Establishment of plasmacytoid dendritic cell-based immune therapy against viral hepatitis and hepatocellular carcinoma
基于浆细胞样树突状细胞的病毒性肝炎和肝细胞癌免疫疗法的建立
基本信息
- 批准号:16590592
- 负责人:
- 金额:$ 2.56万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2004
- 资助国家:日本
- 起止时间:2004 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The aim of the research project was to clarify the roles of dendritic cells (DC), including myeloid DC (MDC) or plasmacytoid DC (PDC), in the pathogenesis of hepatitis C virus-induced chronic hepatitis and hepatocellular carcinoma (HCC). In addition, we aimed to clarify the roles of DC system in the efficacy of IFN-a-based anti-HCV treatment.The frequencies of blood MDC and PDC were decreased in HCV-infected patients compared to healthy donors. The abilities of both DC subsets, such as cytokine production and stimulation of T cells and NK cells, were significantly impaired as well. With regard to the capacity of Th polarization, MDC from the patients were less able to induce Thl response. However, PDC from the patients induced more IL-10-producing regulatory T cells, contributing to the alleviation of liver inflammation:In chronic hepatitis C patients who underwent 48-week peg-IFNα and ribavirin therapy, we examined the frequencies of DC subsets and DC function throughout the therapy. … More In patients who attained sustained virological response (SVR), PDC frequency during the course was higher and DC ability at the end of therapy was better than those in patients who showed transient response (TR). These results demonstrate that maintenance of PDC frequency and DC function are involved in the IFN-mediated HCV eradication.Dendritic cells utilize toll-like receptors (TLR), RIG-I and MDA-5 to sense virus and induce innate as well as adaptive immune responses. The expressions of TLR2,TLR4 and RIG-I in patients MDC were significantly higher than those in donor MDC. In contrast, TLR3 and MDA-5 expressions were comparable between them. When stimulated with specific agonists against TLR2,TLR3,TLR4 and RIG-I, MDC from the patients induced significantly less IFN-β and TNF-α, indicating signal transduction in the downstream of TLR and RIG-I was impaired in MDC from the patients. From the comprehensive RT-PCR analyses, the levels of TRIF and TRAF6 expression were significantly decreased in patient MDC, suggesting the possible role in HCV-induced signal interference.In summary, DC system is a critical target of anti-HCV immune therapy: enhancing function of MDC leads to HCV eradication and that of PDC for retardation of disease progression, respectively. Less
该研究项目的目的是阐明树突状细胞(DC),包括髓样DC (MDC)或浆细胞样DC (PDC),在丙型肝炎病毒诱导的慢性肝炎和肝细胞癌(HCC)的发病机制中的作用。此外,我们旨在阐明DC系统在基于ifn的抗hcv治疗疗效中的作用。与健康献血者相比,hcv感染患者血液中MDC和PDC的频率降低。两个DC亚群的能力,如细胞因子的产生和T细胞和NK细胞的刺激,也明显受损。在Thl极化能力方面,患者的MDC诱导Thl反应的能力较弱。然而,来自患者的PDC诱导了更多产生il -10的调节性T细胞,有助于减轻肝脏炎症:在接受48周peg-IFNα和利巴韦林治疗的慢性丙型肝炎患者中,我们检查了整个治疗过程中DC亚群的频率和DC功能。在获得持续病毒学应答(SVR)的患者中,治疗过程中PDC频率更高,治疗结束时DC能力优于出现短暂应答(TR)的患者。这些结果表明,PDC频率和DC功能的维持与ifn介导的HCV根除有关。树突状细胞利用toll样受体(TLR)、RIG-I和MDA-5感知病毒并诱导先天和适应性免疫反应。TLR2、TLR4和rig - 1在MDC患者中的表达明显高于供体MDC。相比之下,TLR3和MDA-5的表达在两组之间具有可比性。当使用针对TLR2、TLR3、TLR4和RIG-I的特异性激动剂刺激时,来自患者的MDC诱导的IFN-β和TNF-α显著减少,这表明患者MDC中TLR和RIG-I下游的信号转导受损。综合RT-PCR分析,患者MDC中TRIF和TRAF6表达水平显著降低,提示其可能在hcv诱导的信号干扰中起作用。综上所述,DC系统是抗HCV免疫治疗的关键靶点:增强MDC功能可根除HCV,增强PDC功能可延缓疾病进展。少
项目成果
期刊论文数量(108)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection.
- DOI:10.1016/j.hepres.2005.12.010
- 发表时间:2006-03
- 期刊:
- 影响因子:0
- 作者:T. Yakushijin;T. Kanto;M. Inoue;T. Oze;M. Miyazaki;Ichiyo Itose;H. Miyatake;Mitsuru Sakakibara;N. Kuzushita;N. Hiramatsu;T. Takehara;A. Kasahara;N. Hayashi
- 通讯作者:T. Yakushijin;T. Kanto;M. Inoue;T. Oze;M. Miyazaki;Ichiyo Itose;H. Miyatake;Mitsuru Sakakibara;N. Kuzushita;N. Hiramatsu;T. Takehara;A. Kasahara;N. Hayashi
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses
- DOI:10.1053/j.gastro.2004.07.019
- 发表时间:2004-10-01
- 期刊:
- 影响因子:29.4
- 作者:Takehara, T;Tatsumi, T;Hayashi, N
- 通讯作者:Hayashi, N
Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection
- DOI:10.1111/j.1365-2893.2006.00814.x
- 发表时间:2007-06-01
- 期刊:
- 影响因子:2.5
- 作者:Miyatake, H.;Kanto, T.;Hayashi, N.
- 通讯作者:Hayashi, N.
Impaired ability of interferon-alpha-primed dendritic cells to stimulate Thl-type CD4 T cell response in chronic hepatitis C virus infection.
在慢性丙型肝炎病毒感染中,干扰素α引发的树突状细胞刺激Thl型CD4 T细胞反应的能力受损。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Miyatake;H.;Kanto;T.;et al.
- 通讯作者:et al.
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
慢性丙型肝炎患者在干扰素加利巴韦林联合治疗期间,血红蛋白的早期下降与利巴韦林诱导的溶血性贫血的进展相关。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Uno S;et al.;Wada A;Ujiie H;Matsumoto H;Fukui K;Oze T
- 通讯作者:Oze T
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KANTO Tatsuya其他文献
KANTO Tatsuya的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KANTO Tatsuya', 18)}}的其他基金
Development of novel therapy for hepatocellular carcinoma targeting of bone marrow-derived angiogenesis precursor
以骨髓源性血管生成前体为靶点的肝细胞癌新疗法的开发
- 批准号:
22590729 - 财政年份:2010
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developmental research on dendritic cell-based immunotherapy against chronic hepatitis C and hepatocellular carcinoma
基于树突状细胞的慢性丙型肝炎和肝细胞癌免疫治疗的进展研究
- 批准号:
19590765 - 财政年份:2007
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
- 批准号:31272541
- 批准年份:2012
- 资助金额:82.0 万元
- 项目类别:面上项目
相似海外基金
Impacts of the migratory dendritic cells on tumor-specific T cell fate in the thymus
迁移树突状细胞对胸腺中肿瘤特异性 T 细胞命运的影响
- 批准号:
24K18461 - 财政年份:2024
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: Understanding the Immunometabolism-Epigenetic Crosstalk in Dendritic Cells
职业:了解树突状细胞中的免疫代谢-表观遗传串扰
- 批准号:
2412256 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Continuing Grant
Effector-triggered immunity against Legionella pneumophila in dendritic cells
树突状细胞中针对嗜肺军团菌的效应子触发免疫
- 批准号:
10753211 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Unified mechanism elucidation of efficacy and side effects of JAK inhibition by targeting dendritic cells
通过靶向树突状细胞抑制 JAK 的功效和副作用的统一机制阐明
- 批准号:
23K06897 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Homeostatic maintenance and activation of dental pulp quiescent stem/progenitor cells regulated by dendritic cells and macrophages
树突状细胞和巨噬细胞调节的牙髓静止干/祖细胞的稳态维持和激活
- 批准号:
23H03078 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of a new cancer immunotherapy using the exosome derived from neoantigen pulsed mature dendritic cells
使用源自新抗原脉冲成熟树突状细胞的外泌体开发新的癌症免疫疗法
- 批准号:
23K08073 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The research of targeting tumor-associated dendritic cells, a new therapy strategy by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses
靶向肿瘤相关树突状细胞的研究,树突状细胞介导肿瘤相关抗原的摄取和抗肿瘤反应的新治疗策略
- 批准号:
23K14668 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The role of plasmacytoid dendritic cells in corneal immunity
浆细胞样树突状细胞在角膜免疫中的作用
- 批准号:
10640026 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:
Ontogeny and Function of Early-Life Pulmonary Dendritic Cells
早期肺树突状细胞的个体发育和功能
- 批准号:
10667996 - 财政年份:2023
- 资助金额:
$ 2.56万 - 项目类别:














{{item.name}}会员




